Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα
Elisavet Serti, Heiyoung Park, Meghan Keane, Ashley C O'Keefe, Elenita Rivera, T Jake Liang, Marc Ghany, Barbara Rehermann, Elisavet Serti, Heiyoung Park, Meghan Keane, Ashley C O'Keefe, Elenita Rivera, T Jake Liang, Marc Ghany, Barbara Rehermann
Abstract
Objective: Chronic HCV infection is characterised by innate immune activation with increased interferon-stimulated genes (ISG) expression and by an altered phenotype of interferon-responsive natural killer (NK) cells. Here, we asked whether a rapid reduction in viremia by daclatasvir (DCV) and asunaprevir (ASV) improves the response to pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy.
Design: Twenty-two HCV-infected non-responders to previous PegIFN/RBV therapy were studied for IFN-responsiveness of NK cells during quadruple (QUAD) therapy with DCV, ASV, PegIFN and RBV. A direct comparison of early NK cell responses in PegIFN/RBV therapy and QUAD therapy was performed for seven patients using paired cryopreserved peripheral blood mononuclear cells (PBMC) from both treatment courses. As a validation cohort, nine DCV/ASV-treated patients were studied for their NK cell response to in vitro stimulation with IFNα.
Results: The 24 h virological response to QUAD therapy correlated with an increase in signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1 (pSTAT1) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in NK cells, and the STAT1/pSTAT1/TRAIL induction was greater during QUAD therapy than during previous PegIFN/RBV therapy. Successful QUAD therapy as well as successful IFN-free DCV/ASV regimen resulted in an improved functional NK cell response (degranulation and TRAIL expression) to in vitro stimulation with IFNα.
Conclusions: IFN-responsiveness can be improved by inhibiting HCV replication and reducing the HCV-induced activation of the innate immune response. This may provide a rationale for clinical trials of a brief period of direct acting antiviral therapy followed by PegIFN/RBV therapy to reduce the overall treatment costs in low-income and middle-income countries.
Trial registration numbers: NCT01888900 and NCT00718172.
Keywords: HEPATITIS C; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOLOGY IN HEPATOLOGY.
Conflict of interest statement
COMPETING INTERESTS
The authors do not have a commercial or other association that might pose a conflict of interest.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Figures









Source: PubMed
다가오는 임상 시험
-
Shirley Ryan AbilityLabKiwanis Neurological Research Foundation모병
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)아직 모집하지 않음
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La Fe모병
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik Floridsdorf아직 모집하지 않음
-
Beijing Suncadia Pharmaceuticals Co., Ltd모병
-
Xiangya Hospital of Central South University아직 모집하지 않음
-
Halic University아직 모집하지 않음수면의 질 | 식이 중재 | 인지된 스트레스 | 브레인 포그터키 (Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University아직 모집하지 않음전이성 유방암 | 호르몬 수용체 양성 유방암 | HER2-낮은 유방암중국
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., Ltd아직 모집하지 않음
-
University Hospital, Montpellier아직 모집하지 않음
-
Kasr El Aini Hospital모병